ANXA2 and hepatocellular carcinoma: In addition to ANXA2, high expressions of other Annexin proteins were also reported to be associated with therapeutic resistance in different cancers, such as ANXA1 against chemo−/radiotherapy in the CNE2 NPC cell line [14, 15], ANXA2 against multiple drugs in NPC, gastric cancer, breast cancer, and pancreatic cancer [8, 62–64], ANXA3 against chemotoxicity in HCC patients (n = 34) [65], and ANXA4 against chemotherapeutic drugs in human ovarian (OVTOKO and OVISE), lung (H460) and colorectal (HCT15) cancer cells [66, 67].